



Vitamins B during LCIG infusion

possible strategy to reduce peripheral neuropathy

V. Rispoli^{1,2}, V. Simioni³, J. Capone³, N. Golfrè Andreasi^{1,2}, E. Sette³, E. Contini³, V. Tugnoli³, M.Sensi³

Clinical Neurology Unit, Department of Neuroscience/Rehabilitation, Sant'Anna Hospital, University of Ferrara, Ferrara, Italy


² Department of Biomedical and Specialty Surgical Sciences, University of Ferrara, Ferrara, Italy

³ Neurology Unit, Department of Neuroscience/Rehabilitation, Sant'Anna Hospital, University of Ferrara, Ferrara, Italy

Objectives

- Incidence of new onset peripheral neuropathy (post-PN)
- Evolution of pre-existing PN (pre-PN)

in 32 Parkinson's disease (PD) patients treated with Levodopa/Carbidopa IntestinalGel (LCIG) and with vitamins B oral supplementation since PEG-J implant as influence of levodopa on 1-carbon pathway was hypothesized.



Methods:

• UPDRS-III

UPDRS-IV

- **Motor outcome**
- H&Y

 \bullet

- ONLS [0-12] (disability)
 MRC-SS [0-60] (motor)
 INCAT [0-20] (disability)
- Neurophysiological tests (upper and lower limbs)
- SAP of ulnar, median, radial and sural nerves
- cMAP of median, ulnar, peroneal and tibial nerves

Biochemical protocol:

- vitamin B 12 dosage
- Homocysteine (Hcy) dosage
- Folate dosage

Fig.1: sural SAP amplitude: dot line as threshold (>4 μ V) of normal value **Fig.2**, **Fig.3**: vit. B12 and folate blood dosage **Fig 4**, **Fig.5**, **Fig6**: clinical scales on neuropathy

Results and Discussion:

- \rightarrow progressive reduction of sural SAP and common peroneal cMAP amplitude in all 32 patients enrolled (mean follow-up 45.4 months).
- \rightarrow pre-PN patients, SAPs and cMAPs decreased slightly and steadily.
- → among who has normal clinical-electrophysiological assessment at baseline (22/32), four (18.02%) developed an asymptomatic chronic distal symmetrical axonal PN(post-PN)
- \rightarrow No case of acute or subacute PN or LCIG interruption was documented.
- \rightarrow Vit. B12, Folate, Hcy fluctuated within range of normality during the whole follow-up.
- \rightarrow No correlation with Hcy, age, sex, BMI, Levodopa dosage and duration of levodopa administration was disclosed
- \rightarrow All post-PN patients had early onset of PD and long history of oral LD intake.

Conclusions:

- \approx Possible role of vitamins B therapy in decreasing the incidence or delaying the onset of PN in LCIG-PD patients.
- \approx Early PD's onset and long history of oral LD intake prior to LCIG may be considered risks factors to develop PN after PEGJ implant

Bibliography

